kesimpta 20 mg/0.4 ml solucion inyectable
novartis biosciences peru s.a. - droguerÍa - ofatumumab - solucion inyectable - 20 mg/0.4ml - por jeringa precargada 1.00 u - - ofatumumab
kesimpta
novartis ireland ltd - ofatumumab - la esclerosis múltiple remitente-recurrente - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
kesimpta
novartis pharma ag suiza - ofatumumab (omb157) 20 mg/0,4 ml - solucion inyectable - caja jeringa de 0,4 ml contiene: ofatumumab (omb157) 20,000 mg